To test this, we performed a GSEA analysis between patients with low/high 25% of PSI changes of PTK2 cassette exon 31 from the TCGA GBM cohort, and found a significant enrichment of angiogenesis pathway in patients with PTK2 exon 31 skipping, which is more presented in our Foretinib resistant group (Figure S5D,E, Supporting Information). The gene discussed is PTK2; the disease is glioblastoma.